AWA
MDGL icon

Aaron Wealth Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

Aaron Wealth Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-123
Closed -$12.1K – 574
2022
Q1 		$12.1K Buy
+123
New +$10.4K ﹤0.01% 750

Other funds holding MDGL

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Aaron Wealth Advisors's MDGL Position: Q2 2022 in Review

Aaron Wealth Advisors sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2022, closing a stake of 123 shares — an estimated $12.1K sold.

Aaron Wealth Advisors first reported a position in MDGL in Q1 2022 and held it in 1 quarter. The position peaked at $12.1K in Q1 2022. 138 funds tracked by Wall St. Rank hold MDGL as of Q2 2022.

  • Aaron Wealth Advisors reported no remaining Madrigal Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Aaron Wealth Advisors sold 123 Madrigal Pharmaceuticals shares in Q2 2022, an estimated $12.1K.
  • Aaron Wealth Advisors first reported a position in Madrigal Pharmaceuticals in Q1 2022 and held it in 1 quarter.
  • Aaron Wealth Advisors's Madrigal Pharmaceuticals position peaked at $12.1K in Q1 2022.
  • 138 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2022.

Based on Aaron Wealth Advisors's 13F filing for Q2 2022, filed 22 Jul 2022.